Bioavailability enhancement

Bioavailability enhancement

Our science-driven strategy for enhancing bioavailability in formulations saves you time and money while optimizing clinical drug substances and materials.

Innovative. Efficient. We streamline your development and expedite your journey to clinical trials.

Solving your solubility challenge efficiently

We help solve solubility challenges that impact your drug candidate’s reproducible absorption in the gastrointestinal tract. Where poor drug substance solubility limits oral bioavailability, we have dedicated technologies and expertise to apply formulation techniques that increase dissolution rate and/or apparent solubility at the absorption site.

Understanding the physicochemical and biological properties of a drug substance is key to assessing its developability and selecting the right technology to solve solubility challenges. Using a science-led approach, we offer integrated solutions to meet your needs efficiently, cost-effectively, and with minimal API requirements.

We use screening to identify the most effective formulation technology for your compound, developed in our formulation laboratory and with facilities engineered to ensure a seamless transition to GMP manufacturing. With our enabling technologies, we deliver scalable and stable first-in-human formulations and can support your product through Phase I, II, and III clinical trials, to small-batch commercial manufacturing.

With a range of solubility-enhancing methods and technologies, our approach optimizes project timelines and quality while minimizing costs and risks.

Solid dispersions

Solid dispersions

Amorphous solid dispersions increase solubility by eliminating the impact of crystal lattice energy on the dissolution process. The conversion of the crystalline drug substance into an amorphous form, along with the physical stabilization of the amorphous state within a polymer matrix, is achieved through spray drying (a solvent-based method) or hot melt extrusion (a fusion-based method).

Polymers with sufficient solid-state miscibility with the drug substance are carefully identified to prevent recrystallization and ensure consistent performance over time. This is achieved using precise techniques conducted at a milligram scale.

Additional components that improve processability, bioavailability, or physical and chemical stability can be incorporated into amorphous solid dispersion formulations as needed. The selection and quantity of such additives are determined on a case-by-case basis, guided by robust scientific rationale.

Formulation concepts demonstrating adequate performance and physical stability are subsequently scaled up and GMP-manufactured for clinical supply.

Lipid-based formulations

Lipid-based formulations

Lipid-based delivery systems range from simple oil solutions to complex mixtures of oils, surfactants, co-surfactants and co-solvents. These formulations present the drug substance to the body in a pre-dissolved state and increase oral bioavailability primarily by enhancing the solubilizing capacity of the gastrointestinal environment.

The development of lipid formulations is often complex due to the wide variety of lipophilic excipients available and the intricacies of their interplay. Our science-based approach ensures a balance of solubilizing capacity, in vitro performance, and manufacturability.

Nanosuspensions

Nanosuspensions

Nanosuspensions show accelerated dissolution rates as a result of reducing the particle size, which leads to an increased surface area of these particles. The key to nanosuspension development is the identification of a suitable stabilizer system, such that crystal growth and agglomeration effects are suppressed during the lifetime of the formulation.

In addition to a broad range of milling systems, we have the technologies to convert (liquid) nanosuspensions into solid forms.

Related resources

Our team members share their deep, scientific understanding and insights into bioavailability enhancement.

Your molecule, your journey, our mission.

Get in touch to see how we can craft your path to the clinic with dedicated capabilities.

Our integrated platforms

Program management

Using the right standards at the right development phase, our comprehensive program management services streamline your small molecule drug development.

Drug substance

Helping you turn your compounds that show promise into GMP-grade drug substances.

Drug product

We advance your clinical candidates through the pipeline quickly and safely with specialist drug product services.

Bioanalysis

Our bioanalytical platform supports your preclinical and clinical stages with expert testing services.

CMC regulatory services

Our comprehensive CMC regulatory services streamline preparation and submission of your registration file.

Program management

Using the right standards at the right development phase, our comprehensive program management services streamline your large molecule drug development.

Drug product

We advance your large molecule candidates through the pipeline quickly and safely with specialist drug product services.

Bioanalysis

Our bioanalytical platform supports your large molecule drugs through preclinical and clinical stages with expert testing services.

CMC regulatory services

Our comprehensive CMC regulatory services streamline the preparation and submission of the regulatory files for your large molecule drug.

Program management

Using the right standards at the right development phase, our comprehensive program management services streamline your nanomedicine drug development.

Drug product

We turn your nanomedicine candidates into suitable drugs with specialist development and manufacturing services.

Bioanalysis

Our bioanalytical platform supports your preclinical and clinical stages with expert testing services.

CMC regulatory services

Our comprehensive CMC regulatory services streamline the preparation and submission of the regulatory files for your nanomedicines.